Header Logo

Connection

ERIC BOERWINKLE to Pharmacogenetics

Back to Details
This is a "connection" page, showing publications ERIC BOERWINKLE has written about Pharmacogenetics.
ERIC BOERWINKLE
Connection Strength
1.993
Pharmacogenetics
  1. Pharmacogenetics of response to statins: where do we stand? Curr Atheroscler Rep. 2005 May; 7(3):204-8.
    View in: PubMed
    Score: 0.223
  2. Implementation of preemptive DNA sequence-based pharmacogenomics testing across a large academic medical center: The Mayo-Baylor RIGHT 10K Study. Genet Med. 2022 05; 24(5):1062-1072.
    View in: PubMed
    Score: 0.179
  3. Antihypertensive pharmacogenetics: getting the right drug into the right patient. J Hypertens. 2001 Jan; 19(1):1-11.
    View in: PubMed
    Score: 0.165
  4. Cohort Profile: The Right Drug, Right Dose, Right Time: Using Genomic Data to Individualize Treatment Protocol (RIGHT Protocol). Int J Epidemiol. 2020 02 01; 49(1):23-24k.
    View in: PubMed
    Score: 0.155
  5. Pharmacogenomic Genome-Wide Meta-Analysis of Blood Pressure Response to ?-Blockers in Hypertensive African Americans. Hypertension. 2016 Mar; 67(3):556-63.
    View in: PubMed
    Score: 0.117
  6. Pharmacogenomics of hypertension: a genome-wide, placebo-controlled cross-over study, using four classes of antihypertensive drugs. J Am Heart Assoc. 2015 Jan 26; 4(1):e001521.
    View in: PubMed
    Score: 0.109
  7. Pharmacogenetic effects of 'candidate gene complexes' on stroke in the GenHAT study. Pharmacogenet Genomics. 2014 Nov; 24(11):556-63.
    View in: PubMed
    Score: 0.108
  8. Drug-gene interactions and the search for missing heritability: a cross-sectional pharmacogenomics study of the QT interval. Pharmacogenomics J. 2014 Feb; 14(1):6-13.
    View in: PubMed
    Score: 0.096
  9. Systems biology data analysis methodology in pharmacogenomics. Pharmacogenomics. 2011 Sep; 12(9):1349-60.
    View in: PubMed
    Score: 0.086
  10. Pharmacogenetic association of hypertension candidate genes with fasting glucose in the GenHAT Study. J Hypertens. 2010 Oct; 28(10):2076-83.
    View in: PubMed
    Score: 0.081
  11. Genetic discoveries and nursing implications for complex disease prevention and management. J Prof Nurs. 2004 Jul-Aug; 20(4):222-9.
    View in: PubMed
    Score: 0.053
  12. Pharmacogenetic approaches to hypertension therapy: design and rationale for the Genetics of Hypertension Associated Treatment (GenHAT) study. Pharmacogenomics J. 2002; 2(5):309-17.
    View in: PubMed
    Score: 0.044
  13. Genetic testing in ambulatory cardiology clinics reveals high rate of findings with clinical management implications. Genet Med. 2021 12; 23(12):2404-2414.
    View in: PubMed
    Score: 0.043
  14. Genome-Wide Meta-Analysis of Blood Pressure Response to ?1-Blockers: Results From ICAPS (International Consortium of Antihypertensive Pharmacogenomics Studies). J Am Heart Assoc. 2019 08 20; 8(16):e013115.
    View in: PubMed
    Score: 0.037
  15. Genome-Wide Association Approach Identified Novel Genetic Predictors of Heart Rate Response to ?-Blockers. J Am Heart Assoc. 2018 02 24; 7(5).
    View in: PubMed
    Score: 0.034
  16. Sphingolipid Metabolic Pathway Impacts Thiazide Diuretics Blood Pressure Response: Insights From Genomics, Metabolomics, and Lipidomics. J Am Heart Assoc. 2017 12 29; 7(1).
    View in: PubMed
    Score: 0.033
  17. Genetic Variants Associated With Uncontrolled Blood Pressure on?Thiazide Diuretic/?-Blocker Combination Therapy in the PEAR (Pharmacogenomic Evaluation of Antihypertensive Responses)?and INVEST (International Verapamil-SR Trandolapril Study) Trials. J Am Heart Assoc. 2017 Nov 02; 6(11).
    View in: PubMed
    Score: 0.033
  18. Genome-Wide Prioritization and Transcriptomics Reveal Novel Signatures Associated With Thiazide Diuretics Blood Pressure Response. Circ Cardiovasc Genet. 2017 Jan; 10(1).
    View in: PubMed
    Score: 0.031
  19. A Genetic Response Score for Hydrochlorothiazide Use: Insights From Genomics and Metabolomics Integration. Hypertension. 2016 09; 68(3):621-9.
    View in: PubMed
    Score: 0.030
  20. The effects of genes implicated in cardiovascular disease on blood pressure response to treatment among treatment-naive hypertensive African Americans in the GenHAT study. J Hum Hypertens. 2016 09; 30(9):549-54.
    View in: PubMed
    Score: 0.029
  21. PTPRD gene associated with blood pressure response to atenolol and resistant hypertension. J Hypertens. 2015 Nov; 33(11):2278-85.
    View in: PubMed
    Score: 0.029
  22. TET2 and CSMD1 genes affect SBP response to hydrochlorothiazide in never-treated essential hypertensives. J Hypertens. 2015 Jun; 33(6):1301-9.
    View in: PubMed
    Score: 0.028
  23. Pharmacogenetic meta-analysis of genome-wide association studies of LDL cholesterol response to statins. Nat Commun. 2014 Oct 28; 5:5068.
    View in: PubMed
    Score: 0.027
  24. Hydrochlorothiazide-induced hyperuricaemia in the pharmacogenomic evaluation of antihypertensive responses study. J Intern Med. 2014 Nov; 276(5):486-97.
    View in: PubMed
    Score: 0.026
  25. PROX1 gene variant is associated with fasting glucose change after antihypertensive treatment. Pharmacotherapy. 2014 Feb; 34(2):123-30.
    View in: PubMed
    Score: 0.025
  26. Hypertension susceptibility loci and blood pressure response to antihypertensives: results from the pharmacogenomic evaluation of antihypertensive responses study. Circ Cardiovasc Genet. 2012 Dec; 5(6):686-91.
    View in: PubMed
    Score: 0.023
  27. G protein receptor kinase 4 polymorphisms: ?-blocker pharmacogenetics and treatment-related outcomes in hypertension. Hypertension. 2012 Oct; 60(4):957-64.
    View in: PubMed
    Score: 0.023
  28. Association of KCNJ1 variation with change in fasting glucose and new onset diabetes during HCTZ treatment. Pharmacogenomics J. 2013 Oct; 13(5):430-6.
    View in: PubMed
    Score: 0.023
  29. Pharmacogenetic associations of MMP9 and MMP12 variants with cardiovascular disease in patients with hypertension. PLoS One. 2011; 6(8):e23609.
    View in: PubMed
    Score: 0.022
  30. Pharmacogenomics of antihypertensive drugs: rationale and design of the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) study. Am Heart J. 2009 Mar; 157(3):442-9.
    View in: PubMed
    Score: 0.018
  31. Genomic association analysis suggests chromosome 12 locus influencing antihypertensive response to thiazide diuretic. Hypertension. 2008 Aug; 52(2):359-65.
    View in: PubMed
    Score: 0.017
  32. Pharmacogenetic association of the NPPA T2238C genetic variant with cardiovascular disease outcomes in patients with hypertension. JAMA. 2008 Jan 23; 299(3):296-307.
    View in: PubMed
    Score: 0.017
  33. Absence of an interaction between the angiotensin-converting enzyme insertion-deletion polymorphism and pravastatin on cardiovascular disease in high-risk hypertensive patients: the Genetics of Hypertension-Associated Treatment (GenHAT) study. Am Heart J. 2007 Jan; 153(1):54-8.
    View in: PubMed
    Score: 0.016
  34. Pharmacogenetic association of the angiotensin-converting enzyme insertion/deletion polymorphism on blood pressure and cardiovascular risk in relation to antihypertensive treatment: the Genetics of Hypertension-Associated Treatment (GenHAT) study. Circulation. 2005 Jun 28; 111(25):3374-83.
    View in: PubMed
    Score: 0.014
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.